Combination of FasL and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 123-133

  Ho, Ming Yi ^a   Sun, Guang Huan ^c   Leu, Shr Jeng Jim ^a,b   Ka, Shuk Man ^c   Tang, Shye Jye ^d   Sun, Kuang Hui ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Fas ligand (fasL); Granulocyte macrophage colony stimulating factor (GM CSF); Lung cancer; Th1 immune response

Indexed keywords

CANCER VACCINE; DOXORUBICIN; FAS LIGAND; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENTIATION; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO GENE TRANSFER; IN VIVO STUDY; INOCULATION; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIGEN PRESENTATION; BLOTTING, WESTERN; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CYTOKINES; DENDRITIC CELLS; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOPRECIPITATION; INTERLEUKIN-12; INTERLEUKIN-1BETA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 43949093802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23474     Document Type: Article

References (36)

1. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002;59:611-42.
2. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nature Med 2004;10:887-92.
3. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
4. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999;27:58-63.
5. Nagata S, Sucla T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
6. O'Connell J, O'sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J. Exp Med 1996;184:1075-82.
7. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001;167:6217-24.
8. Tada Y, Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Okada S, Tokuhisa T, Sakiyama S, Tagawa M. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 2002;169:2241-5.
9. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol 1999;162:7350-7.
10. Seino K, Kavagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
11. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18-27.
12. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998;91:222-30.
13. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Hamada H, Azuma M, Asano S. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. Int J Cancer 1997;73:556-61.
14. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997;4:345-52.
15. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Wu MS, Izawa K, Hamada H, Asano S. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. Cancer Gene Ther 1998;5:29-37.
16. Kojima T, Yamazaki K, Tamura Y, Ogura S, Tani K, Konishi J, Shinagawa N, Kinoshita I, Hizawa N, Yamaguchi E, Dosaka-Akita H, Nishimura M. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum Gene Ther 2003;14:715-28.
17. Yang J, Kanter G, Voloshin A, Michel-Reydellet N, Velkeen H, Levy R, Swartz JR. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng 2005;89:503-11.
18. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology 2001;40:750-6.
19. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
20. Das S, Khar A. Regulation of NK cell function in vivo by the dose of tumour transplanted in the peritoneum. Immunol Lett 2002;83:133-42.
21. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002;41:57-77.
22. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor β in tumor progression. Cancer 2004;100:2281-91.
23. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000;10:640-8.
24. Rescigno M, Piguet V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J, Ricciardi-Castagnoli P. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med 2000;192:1661-8.
25. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
26. Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med 1999;189:231-9.
27. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000;165:3772-81.
28. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-6.
29. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
30. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-50.
31. + T cells responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
32. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185-93.
33. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43.
34. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999;10:1983-91.
35. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
36. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-32.